{
  "docId": "019de073-dc46-770c-87a2-2b21d91043e5",
  "docSlug": "4f9fcbb83e828aea5419518c9cca9ae9",
  "documentTitle": "Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides",
  "authorId": "tonix-pharmaceuticals",
  "authorName": "Tonix Pharmaceuticals",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 29,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-dc46-770c-87a2-2b21d91043e5/4",
  "deckHref": "/decks/019de073-dc46-770c-87a2-2b21d91043e5",
  "deckJsonHref": "/decks/019de073-dc46-770c-87a2-2b21d91043e5.json",
  "deckAnchorHref": "/decks/019de073-dc46-770c-87a2-2b21d91043e5#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.72,
        "w": 0.12,
        "x": 0.035,
        "y": 0.185
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9d80466-0170-4564-a3c2-6885d7469acc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.865,
        "x": 0.044,
        "y": 0.815
      },
      "kind": "list",
      "text": "FINANCIAL POSITION: Tonix had $145.5 M of cash as of 6/30/22. Tonix has no debt.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c857283-7110-4342-8b10-673158d64d7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.085,
        "w": 0.865,
        "x": 0.044,
        "y": 0.415
      },
      "kind": "list",
      "text": "STRATEGIC PARTNERSHIPS: Partnering strategically with other biotech companies, world-class academic and non-profit research organizations to bring innovative therapeutics to market faster.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "117f8c3e-4970-49cd-81f3-f93bf22bc808",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.085,
        "w": 0.865,
        "x": 0.044,
        "y": 0.615
      },
      "kind": "list",
      "text": "IN-HOUSE CAPABILITIES: Investment in domestic, in-house, R&D and manufacturing to accelerate development timelines and improve the ability to respond to pandemics.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50e48c79-3be2-44e3-b529-a0a8042e98eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.175,
        "w": 0.865,
        "x": 0.044,
        "y": 0.185
      },
      "kind": "list",
      "text": "DIVERSE PIPELINE: Tonix's core focus is on central nervous system disorders, but we also target unmet needs across multiple therapeutic areas including immunology, infectious disease and rare disease. Tonix is currently enrolling participants in one Phase 3 trial and one Phase 2 trial. We expect six additional clinical trials to commence in the next 12 months.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d59dc5bf-6714-4c11-813a-5ce69bc30b5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.042,
        "w": 0.191,
        "x": 0.044,
        "y": 0.096
      },
      "kind": "title",
      "text": "What We Do",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35ff0b51-edc3-42f0-bcd8-a8bcd945cbcb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "710e3b7d-6026-4c33-a0a6-e504c96657ae",
      "evidence": "paragraph/paragraph: OUR MISSION",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 3,
      "beatId": "cbbe0177-fd25-4450-9e5b-41d95c7043ab",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The presentation introduces the company's pipeline and key programs",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 29,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "e532f435-d20e-4323-8595-44dab22c3ce1",
      "evidence": "The presentation uses a golden circle structure to communicate the company's mission and vision",
      "position": 0,
      "objective": "Why Tonix Pharmaceuticals?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}